Table 1.
Baseline clinical, metabolic and biochemical characteristics.
| Sex M/F | 43 (58.9)/30 (41.1) |
| Age, years | 47.2 ± 8.5 |
| Time since diagnose, years | 22.4 ± 2.2 |
| Insulin dose, Ui/kg/day | 0.6 ± 0.2 |
| Weight, kg | 77.8 ± 17.7 |
| BMI, kg/m2 | 26.9 ± 4.6 |
| WC, cm | 93.9 ± 13.1 |
| Type of treatment, BBT/CSII | 62 (84.9)/11 (15.1) |
| Smoking status | |
| Smoker | 25 (34.2) |
| Former smoker | 22 (30.1) |
| Non smoker | 26 (35.6) |
| Dyslipidemia | 40 (54.8) |
| Hypolipidemic treatment | 34 (46.6) |
| Statin treatment | 33 (45.2) |
| Statins and ezetimibe treatment | 1 (1.4) |
| Hypertension | 23 (31.5) |
| Diabetic retinopathy | 13 (18.1) |
| Diabetic nephropathy | 8 (11) |
| Diabetic neuropathy | 12 (16.4) |
| CAD | 1 (1.4) |
| Stroke | 1 (1.4) |
| Peripheral arterial disease | 2 (2.8) |
| HbA1c, % (mmol/mol) | 7.6 (60 mmol/mol) ± 1.1 |
| ACR, mg/mmol | 2.2 ± 0.7 |
| Total cholesterol, mmol/L | 4.77 ± 0.72 |
| HDL cholesterol, mmol/L | 1.48 ± 0.30 |
| LDL cholesterol, mmol/L | 2.83 ± 0.56 |
| VLDL cholesterol, mmol/L | 0.45 ± 0.32 |
| Triglycerides, mmol/L | 1.02 ± 0.9 |
| Apolipoprotein B, g/L | 0.78 ± 0.16 |
| PCSK9, mg/L, | 0.37 ± 0.12 |
Male (M); Female (F); Waist circumference (WC); Basal-bolus therapy (BBT); Continuous Subcutaneous Insulin Infusion (CSII); Coronary artery disease (CAD); Urine Albumin to Creatinine Ratio (ACR); Proconvertase subtilisin-kexin 9 (PCSK9).
The data are expressed as the mean ± SD or n (%).